NASDAQ:ARDX

Ardelyx Competitors

$8.19
-0.06 (-0.73 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.98
Now: $8.19
$8.44
50-Day Range
$6.10
MA: $7.10
$8.81
52-Week Range
$4.96
Now: $8.19
$9.23
Volume1.62 million shs
Average Volume1.46 million shs
Market Capitalization$808.19 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02

Competitors

Ardelyx (NASDAQ:ARDX) Vs. CCXI, MOR, OPK, KRTX, TARO, and PCRX

Should you be buying ARDX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Ardelyx, including ChemoCentryx (CCXI), MorphoSys (MOR), OPKO Health (OPK), Karuna Therapeutics (KRTX), Taro Pharmaceutical Industries (TARO), and Pacira BioSciences (PCRX).

ChemoCentryx (NASDAQ:CCXI) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Profitability

This table compares ChemoCentryx and Ardelyx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChemoCentryx-58.10%-17.23%-11.07%
Ardelyx-1,063.74%-53.93%-37.42%

Volatility and Risk

ChemoCentryx has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.

Institutional and Insider Ownership

80.7% of ChemoCentryx shares are held by institutional investors. Comparatively, 85.9% of Ardelyx shares are held by institutional investors. 9.3% of ChemoCentryx shares are held by insiders. Comparatively, 4.0% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares ChemoCentryx and Ardelyx's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChemoCentryx$36.13 million89.30$-55,490,000.00($0.98)-47.20
Ardelyx$5.28 million153.07$-94,940,000.00($1.47)-5.57

ChemoCentryx has higher revenue and earnings than Ardelyx. ChemoCentryx is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ChemoCentryx and Ardelyx, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChemoCentryx01713.00
Ardelyx00403.00

ChemoCentryx currently has a consensus target price of $80.7778, indicating a potential upside of 74.62%. Ardelyx has a consensus target price of $14.00, indicating a potential upside of 70.94%. Given ChemoCentryx's higher probable upside, analysts plainly believe ChemoCentryx is more favorable than Ardelyx.

Summary

ChemoCentryx beats Ardelyx on 10 of the 14 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Ardelyx and MorphoSys' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ardelyx-1,063.74%-53.93%-37.42%
MorphoSys8.76%4.51%2.25%

Risk and Volatility

Ardelyx has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. Comparatively, 3.1% of MorphoSys shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ardelyx and MorphoSys' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$5.28 million153.07$-94,940,000.00($1.47)-5.57
MorphoSys$80.43 million37.92$-115,380,000.00($0.91)-25.47

Ardelyx has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ardelyx and MorphoSys, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ardelyx00403.00
MorphoSys06402.40

Ardelyx presently has a consensus price target of $14.00, indicating a potential upside of 70.94%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than MorphoSys.

Summary

Ardelyx beats MorphoSys on 7 of the 13 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Ardelyx and OPKO Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ardelyx-1,063.74%-53.93%-37.42%
OPKO Health-9.79%-2.61%-1.80%

Risk and Volatility

Ardelyx has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. Comparatively, 28.5% of OPKO Health shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Comparatively, 40.9% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ardelyx and OPKO Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$5.28 million153.07$-94,940,000.00($1.47)-5.57
OPKO Health$901.90 million3.25$-314,920,000.00($0.41)-10.66

Ardelyx has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ardelyx and OPKO Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ardelyx00403.00
OPKO Health00203.00

Ardelyx presently has a consensus price target of $14.00, indicating a potential upside of 70.94%. OPKO Health has a consensus price target of $9.00, indicating a potential upside of 105.95%. Given OPKO Health's higher probable upside, analysts plainly believe OPKO Health is more favorable than Ardelyx.

Summary

OPKO Health beats Ardelyx on 7 of the 13 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Ardelyx and Karuna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ardelyx-1,063.74%-53.93%-37.42%
Karuna TherapeuticsN/A-13.91%-13.72%

Risk and Volatility

Ardelyx has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Comparatively, 18.1% of Karuna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ardelyx and Karuna Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$5.28 million153.07$-94,940,000.00($1.47)-5.57
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-29.20

Karuna Therapeutics has lower revenue, but higher earnings than Ardelyx. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ardelyx and Karuna Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ardelyx00403.00
Karuna Therapeutics001103.00

Ardelyx presently has a consensus price target of $14.00, indicating a potential upside of 70.94%. Karuna Therapeutics has a consensus price target of $144.70, indicating a potential upside of 34.67%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Karuna Therapeutics.

Summary

Karuna Therapeutics beats Ardelyx on 7 of the 12 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Ardelyx and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ardelyx-1,063.74%-53.93%-37.42%
Taro Pharmaceutical Industries-45.94%10.36%8.38%

Risk and Volatility

Ardelyx has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ardelyx and Taro Pharmaceutical Industries' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$5.28 million153.07$-94,940,000.00($1.47)-5.57
Taro Pharmaceutical Industries$644.77 million4.47$244.24 million$6.3511.87

Taro Pharmaceutical Industries has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ardelyx and Taro Pharmaceutical Industries, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ardelyx00403.00
Taro Pharmaceutical Industries00103.00

Ardelyx presently has a consensus price target of $14.00, indicating a potential upside of 70.94%. Taro Pharmaceutical Industries has a consensus price target of $81.00, indicating a potential upside of 7.44%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Taro Pharmaceutical Industries.

Summary

Taro Pharmaceutical Industries beats Ardelyx on 7 of the 13 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Ardelyx and Pacira BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ardelyx-1,063.74%-53.93%-37.42%
Pacira BioSciences29.95%10.71%4.88%

Risk and Volatility

Ardelyx has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Comparatively, 5.8% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ardelyx and Pacira BioSciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ardelyx$5.28 million153.07$-94,940,000.00($1.47)-5.57
Pacira BioSciences$421.03 million6.71$-11,020,000.00$0.8674.94

Pacira BioSciences has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ardelyx and Pacira BioSciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ardelyx00403.00
Pacira BioSciences04802.67

Ardelyx presently has a consensus price target of $14.00, indicating a potential upside of 70.94%. Pacira BioSciences has a consensus price target of $77.50, indicating a potential upside of 20.25%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Pacira BioSciences.

Summary

Pacira BioSciences beats Ardelyx on 9 of the 14 factors compared between the two stocks.


Ardelyx Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.26-0.4%$3.23 billion$36.13 million-69.04News Coverage
MorphoSys logo
MOR
MorphoSys
0.3$23.18-1.6%$3.05 billion$80.43 million110.39
OPKO Health logo
OPK
OPKO Health
1.9$4.37-0.7%$2.93 billion$901.90 million-24.28News Coverage
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$107.45-0.8%$2.90 billionN/A-53.46
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.39-1.7%$2.88 billion$644.77 million-10.75News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$64.45-1.0%$2.83 billion$421.03 million22.69News Coverage
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.88-2.9%$2.80 billion$306.49 million26.83
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$44.50-2.9%$2.75 billionN/A-24.45
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.53-3.2%$2.74 billion$25 million-9.51Insider Selling
Analyst Revision
News Coverage
Organogenesis logo
ORGO
Organogenesis
1.0$21.33-0.4%$2.73 billion$260.98 million-355.50News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$43.16-2.0%$2.68 billion$2.11 million-9.34Analyst Report
Unusual Options Activity
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.87-1.0%$2.61 billion$182.24 million-8.58Analyst Upgrade
Insider Selling
Xencor logo
XNCR
Xencor
1.0$44.44-4.9%$2.58 billion$156.70 million-31.74
ALX Oncology logo
ALXO
ALX Oncology
1.9$62.66-7.4%$2.51 billionN/A0.00Insider Selling
News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$30.42-3.7%$2.46 billion$60,000.00-9.45Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$34.70-2.2%$2.46 billion$15 million-18.17News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$147.98-2.8%$2.46 billion$120.28 million-149.47Decrease in Short Interest
News Coverage
Cryoport logo
CYRX
Cryoport
1.7$53.01-1.5%$2.42 billion$33.94 million-91.40
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$55.85-2.3%$2.29 billionN/A0.00Analyst Report
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.81-0.0%$2.28 billion$963.01 million14.23
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.86-1.8%$2.20 billion$23.90 million-17.93Analyst Report
Insider Selling
Analyst Revision
News Coverage
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$27.06-0.8%$2.08 billion$103.54 million-20.35
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.29-0.7%$2.07 billionN/A-11.68
Amarin logo
AMRN
Amarin
1.6$5.19-1.9%$2.04 billion$429.76 million-103.78Upcoming Earnings
MacroGenics logo
MGNX
MacroGenics
1.2$33.66-0.1%$2.02 billion$64.19 million-10.75Upcoming Earnings
Analyst Report
Insider Selling
Unusual Options Activity
News Coverage
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.80-1.1%$1.98 billion$410,000.00-6.04
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.87-3.3%$1.98 billionN/A-19.65Unusual Options Activity
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$61.37-4.4%$1.96 billionN/A-26.11
FibroGen logo
FGEN
FibroGen
1.8$21.12-0.3%$1.94 billion$256.58 million-8.09
Generation Bio logo
GBIO
Generation Bio
1.6$34.29-8.0%$1.93 billionN/A0.00
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.70-1.0%$1.90 billion$34.51 million-17.69
Kura Oncology logo
KURA
Kura Oncology
1.6$28.45-1.1%$1.88 billionN/A-17.45News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$26.00-2.1%$1.86 billion$26.87 million-13.61Analyst Report
MORF
Morphic
1.3$56.44-2.1%$1.83 billion$16.98 million-36.18Insider Selling
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00News Coverage
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$19.48-2.3%$1.77 billionN/A-6.93Analyst Downgrade
Increase in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.81-0.4%$1.74 billion$428.41 million15.67Analyst Upgrade
Unusual Options Activity
News Coverage
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$37.30-4.8%$1.74 billionN/A0.00Analyst Upgrade
Insider Selling
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.70-1.9%$1.71 billion$1.63 billion13.90
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$24.40-2.1%$1.68 billion$2.34 million-10.34
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.30-0.3%$1.66 billion$392.76 million12.99Analyst Upgrade
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$18.08-0.4%$1.65 billion$145.97 million-7.32
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.62-1.3%$1.61 billion$320,000.00-8.59
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.00-0.0%$1.59 billionN/A0.00
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.76-2.3%$1.55 billion$82.27 million-18.93
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.2$34.57-3.2%$1.55 billionN/A0.00
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$30.57-1.0%$1.53 billionN/A-3.31Analyst Upgrade
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$43.28-4.1%$1.53 billionN/A0.00Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95-3.7%$1.51 billion$175.34 million-14.68Insider Selling
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.